4.7 Article

CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 208, Issue 13, Pages 2633-2640

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20102575

Keywords

-

Funding

  1. National Institutes of Health (NIH) [DK51362, DK44319, DK53056, DK088199, AI066897]
  2. Harvard Digestive Diseases Center (NIH) [P30DK034854]
  3. High Pointe Foundation
  4. Israel-U.S. Binational Research Award
  5. Canadian Institutes of Health Research
  6. Crohn's & Colitis Foundation of America

Ask authors/readers for more resources

Although carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1) has been viewed as a tumor suppressor, increasing clinical evidence shows that high levels of CEACAM1 expression on tumors correlates with poor prognosis and high risk of metastasis. Here, we examined the consequences of CEACAM1 expression on tumor cells. We show that tumor cell-associated CEACAM1 causes intracellular retention of various NKG2D ligands in mouse and human tumor cells. CEACAM1-silenced tumor cells expressed more cell surface NKG2D ligands and exhibited greater sensitivity to natural killer cell-mediated cytolysis in vitro and rejection in vivo. Our studies reveal a novel mechanism through which CEACAM1-bearing tumor cells may escape immune-surveillance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available